VivoSeq
Oncology

Castration Sensitive Prostate Cancer

4

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Castration Sensitive Prostate Cancer is an early-stage landscape with 4 programs across 5 companies. The most active players are Ferring, Bristol-Myers Squibb, Pfizer. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ferring logo

Ferring

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Astellas logo

Astellas

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Degarelix

Ferring

Ipilimumab

Bristol-Myers Squibb

Phase 32

Mevrometostat

Pfizer

Enzalutamide

Astellas

Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 80% of 5 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
Recruiting·Pfizer logoPfizer·Phase 3·NCT07028853·1,000 enrolled
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02020070·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)